111 lines
39 KiB
Text
111 lines
39 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK548241">
|
|
<meta name="ncbi_domain" content="livertox">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK548241/?report=reader">
|
|
<meta name="ncbi_pagename" content="Severity Grading In Drug Induced Liver Injury - LiverTox - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Severity Grading In Drug Induced Liver Injury - LiverTox - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/livertox/Phenotypes_tumor/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/livertox/CaseReport/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/livertox/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]">
|
|
<meta name="citation_title" content="Severity Grading In Drug Induced Liver Injury">
|
|
<meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases">
|
|
<meta name="citation_date" content="2019/05/04">
|
|
<meta name="citation_pmid" content="31643566">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548241/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Severity Grading In Drug Induced Liver Injury">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases">
|
|
<meta name="DC.Date" content="2019/05/04">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548241/">
|
|
<meta name="description" content="The severity of cases of drug induced liver injury can vary greatly, from mild, transient and asymptomatic elevations in serum enzyme levels to acute liver failure leading rapidly to death or need for liver transplantation. In assessing drug induced liver injury, it is important to categorize severity in an objective manner. However, the variability in manifestations of drug induced liver disease makes it difficult to use a single symptom, laboratory abnormality or outcome to grade severity of injury. As a part of ongoing studies of drug induced liver injury, the Drug-Induced Liver Injury Network (DILIN) developed a 5 point scale for grading the severity of liver injury based upon the presence of jaundice, hospitalization, signs of hepatic or other organ failure, and ultimate outcome.">
|
|
<meta name="og:title" content="Severity Grading In Drug Induced Liver Injury">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="The severity of cases of drug induced liver injury can vary greatly, from mild, transient and asymptomatic elevations in serum enzyme levels to acute liver failure leading rapidly to death or need for liver transplantation. In assessing drug induced liver injury, it is important to categorize severity in an objective manner. However, the variability in manifestations of drug induced liver disease makes it difficult to use a single symptom, laboratory abnormality or outcome to grade severity of injury. As a part of ongoing studies of drug induced liver injury, the Drug-Induced Liver Injury Network (DILIN) developed a 5 point scale for grading the severity of liver injury based upon the presence of jaundice, hospitalization, signs of hepatic or other organ failure, and ultimate outcome.">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548241/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/livertox/Severity/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548241/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8C51447D7F6D6100000000010E00E3.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK548241/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/livertox/Phenotypes_tumor/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">Severity Grading In Drug Induced Liver Injury</div><div class="j">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</div></div><div class="tail"><a href="/books/n/livertox/CaseReport/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK548241/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK548241/&text=Severity%20Grading%20In%20Drug%20Induced%20Liver%20Injury"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/livertox/?report=reader">Title Information</a><a href="/books/n/livertox/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK548241/?report=classic">Switch to classic view</a><a href="/books/NBK548241/pdf/Bookshelf_NBK548241.pdf">PDF (317K)</a><a href="/books/NBK548241/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK548241%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8C51447D7F6D6100000000010E00E3.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK548241_"><span class="title" itemprop="name">Severity Grading In Drug Induced Liver Injury</span></h1><p class="fm-aai"><a href="#_NBK548241_pubdet_">Publication Details</a></p></div></div><div class="body-content whole_rhythm" itemprop="text"><p>The severity of cases of drug induced liver injury can vary greatly, from mild, transient and asymptomatic elevations in serum enzyme levels to acute liver failure leading rapidly to death or need for liver transplantation. In assessing drug induced liver injury, it is important to categorize severity in an objective manner. However, the variability in manifestations of drug induced liver disease makes it difficult to use a single symptom, laboratory abnormality or outcome to grade severity of injury. As a part of ongoing studies of drug induced liver injury, the Drug-Induced Liver Injury Network (DILIN) developed a 5 point scale for grading the severity of liver injury based upon the presence of jaundice, hospitalization, signs of hepatic or other organ failure, and ultimate outcome.</p><ul><li class="half_rhythm"><div><b>1+, Mild:</b> Raised serum aminotransferase or alkaline phosphatase levels or both, but total serum bilirubin <2.5 mg/dL and no coagulopathy (INR <1.5)</div></li><li class="half_rhythm"><div><b>2+, Moderate:</b> Raised serum aminotransferase or alkaline phosphatase levels or both <u>and</u> total serum bilirubin level ≥2.5 mg/dL <u>or</u> coagulopathy (INR ≥1.5) without hyperbilirubinemia</div></li><li class="half_rhythm"><div><b>3+, Moderate to Severe:</b> Raised serum aminotransferase or alkaline phosphatase levels and total serum bilirubin level ≥2.5 mg/dL <u>and</u> hospitalization (or preexisting hospitalization is prolonged) because of the drug induced liver injury</div></li><li class="half_rhythm"><div><b>4+, Severe:</b> Raised serum aminotransferase or alkaline phosphatase levels and serum bilirubin ≥2.5 mg/dL <u>and</u> at least one of the following:</div><ul><li class="half_rhythm"><div>Prolonged jaundice and symptoms beyond 3 months, <u>or</u></div></li><li class="half_rhythm"><div>Signs of hepatic decompensation (INR ≥1.5, ascites, encephalopathy), <u>or</u></div></li><li class="half_rhythm"><div>Other organ failure believed to be related to drug induced liver injury</div></li></ul></li><li class="half_rhythm"><div><b>5+, Fatal:</b> Death or liver transplantation for drug induced liver injury</div></li></ul><p>Severity is also graded on the basis of symptoms, with “S” indicating symptoms believed to be caused by the liver injury and “A” absence of symptoms. Symptoms that qualify as possibly due to liver injury include fatigue, weakness, nausea, right upper quadrant pain, itching, skin rash, jaundice, anorexia or weight loss. In all situations, the symptoms should be judged as being due to the drug induced liver injury. This grading applies mostly to patients with enzyme elevations without jaundice, as it is rare for a patient with jaundice not to have symptoms.</p><p>In prospective clinical trials of medications, standard criteria are used to assess the severity of adverse events including symptoms and laboratory test abnormalities. Adverse events are typically graded on a scale of 0 to 4. Grades for severity of liver test abnormalities and symptoms of liver injury have been developed and standardized and are used in many publications of clinical trials and studies of new medications. A commonly used grading system is that developed by the Acquired Immune Deficiency Syndrome (AIDS) Clinical Trials Group (CTG). In this system, the following levels are used to assess severity, with the values expressed as multiples of the upper limit of the normal range (ULN).</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figSeverityTc"><a href="/books/NBK548241/table/Severity.Tc/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figSeverityTc" rid-ob="figobSeverityTc"><img class="small-thumb" src="/books/NBK548241/table/Severity.Tc/?report=thumb" src-large="/books/NBK548241/table/Severity.Tc/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="Severity.Tc"><a href="/books/NBK548241/table/Severity.Tc/?report=objectonly" target="object" rid-ob="figobSeverityTc">Table</a></h4></div></div><p>Descriptive terms are also applied to these grades, with Grade 1 indicating mild, Grade 2 moderate, and Grade 3 severe and Grade 4 life-threatening values. However, it should be stressed that these terms usually overestimate the severity of drug induced liver injury, as ALT levels of 5 to 10 times the upper limit of normal (~200 to 400 U/L) without symptoms or jaundice cannot be considered severe hepatotoxicity, and should instead be referred to as “Grade 3 ALT elevations”. The grading of liver test elevations is sometimes adjusted to baseline values, particularly in patients with underlying liver disease, such as hepatitis B or C. In these situations, Grade 0 represents values <1.25, Grade 1, 1.25-2.5, Grade 2, 2.6-3.5, Grade 3, 3.6-5, and Grade 4, >5 times baseline. This convention, however, is not always used.</p><p>A similar grading system has been developed by the Cancer Therapy Evalutation Program of the National Cancer Institute (NCI) of the National Institutes of Health, which is referred to as the Common Toxicity Criteria for Adverse Events, version 4.0: CTCAEv4.03. In this system, the following levels are used to assess severity, with the values expressed as multiples of the upper limit of the normal range (ULN).</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figSeverityTd"><a href="/books/NBK548241/table/Severity.Td/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figSeverityTd" rid-ob="figobSeverityTd"><img class="small-thumb" src="/books/NBK548241/table/Severity.Td/?report=thumb" src-large="/books/NBK548241/table/Severity.Td/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="Severity.Td"><a href="/books/NBK548241/table/Severity.Td/?report=objectonly" target="object" rid-ob="figobSeverityTd">Table</a></h4></div></div><p>Descriptive terms are also applied to these grades, with Grade 1 indicating mild, Grade 2 moderate, and Grade 3 severe and Grade 4 life-threatening values. However, it should be stressed that these terms usually overestimate the severity of drug induced liver injury, as ALT levels of 5 to 20 times the upper limit of normal (~400 to 800 U/L) without symptoms or jaundice cannot be considered severe hepatotoxicity, and should instead be referred to as “Grade 3 ALT elevations”. The grading of liver test elevations is sometimes adjusted to baseline values, particularly in patients with underlying liver disease, such as hepatitis B or C. In these situations, Grade 0 represents values <1.00, Grade 1, 1.00-2.5, Grade 2, 2.6-5.0, Grade 3, 5.0-20, and Grade 4, >20 times baseline. This convention, however, is not always used.</p><p>Thus, the two grading systems have slightly different "cutpoints" to separate the different grades of injury. The AIDS Clinical Trials Group requires an enzyme elevation of at least 1.25 times the ULN to warrant the designation of Grade 1 abnormalities, whereas the NCI system uses any elevation above the ULN as Grade 1 enzyme abnormalities. Similarly, Grade 4 abnormalities in the AIDS CTG system are based on enzyme values above 10 times the ULN, whereas the NCI system uses 20 times ULN.</p><p>A problem with all grading systems using the upper limit of normal as an index is that there is little consensus on what the ULN should be or how it should be calculated. Thus, the upper limit of normal of ALT in different testing laboratories can range from 19 to 77 U/L, and some laboratories use a different reference range for women than men. Actually, current automated systems for measuring ALT values yield very similar results and use of common reference limits is reasonable, particularly in multicenter trials. In the LiverTox website, the default ULN for ALT is 40 U/L, alkaline phosphatase 115 U/L and bilirubin 1.2 mg/dL. Serum bilirubin values are particularly confusing when using multiples of the upper limit of normal, as the ULN in different laboratories may be 1.0, 1.2, or 1.5 mg/dL and a Grade 4 elevation may therefore be 10 mg/dL, 12 mg/dL or 15 mg/dL.</p><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK548241_pubdet_">Publication Details</h2><h3>Publication History</h3><p class="small">Last Update: <span itemprop="dateModified">May 4, 2019</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div></div><h3>Publisher</h3><p><a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>, Bethesda (MD)</p><h3>NLM Citation</h3><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Severity Grading In Drug Induced Liver Injury. [Updated 2019 May 4].<span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"><a href="/books/n/livertox/Phenotypes_tumor/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/livertox/CaseReport/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article><article data-type="table-wrap" id="figobSeverityTc"><div id="Severity.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548241/table/Severity.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Severity.Tc_lrgtbl__"><table><thead><tr><th id="hd_h_Severity.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FEATURE</th><th id="hd_h_Severity.Tc_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Grade 0</th><th id="hd_h_Severity.Tc_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Grade 1</th><th id="hd_h_Severity.Tc_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Grade 2</th><th id="hd_h_Severity.Tc_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Grade 3</th><th id="hd_h_Severity.Tc_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Grade 4</th></tr></thead><tbody><tr><td headers="hd_h_Severity.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>ALT</b>
|
|
</td><td headers="hd_h_Severity.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><1.25</td><td headers="hd_h_Severity.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.25-2.5</td><td headers="hd_h_Severity.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>2.5-5.0</td><td headers="hd_h_Severity.Tc_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>5.0-10</td><td headers="hd_h_Severity.Tc_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>10</td></tr><tr><td headers="hd_h_Severity.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>AST</b>
|
|
</td><td headers="hd_h_Severity.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><1.25</td><td headers="hd_h_Severity.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.25-2.5</td><td headers="hd_h_Severity.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>2.5-5.0</td><td headers="hd_h_Severity.Tc_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>5.0-10</td><td headers="hd_h_Severity.Tc_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>10</td></tr><tr><td headers="hd_h_Severity.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Alkaline Phosphatase</b>
|
|
</td><td headers="hd_h_Severity.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><1.25</td><td headers="hd_h_Severity.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.25-2.5</td><td headers="hd_h_Severity.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>2.5-5.0</td><td headers="hd_h_Severity.Tc_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>5.0-10</td><td headers="hd_h_Severity.Tc_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>10</td></tr><tr><td headers="hd_h_Severity.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>GGT</b>
|
|
</td><td headers="hd_h_Severity.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><1.25</td><td headers="hd_h_Severity.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.25-2.5</td><td headers="hd_h_Severity.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>2.5-5.0</td><td headers="hd_h_Severity.Tc_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>5.0-10</td><td headers="hd_h_Severity.Tc_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>10</td></tr><tr><td headers="hd_h_Severity.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Bilirubin</b>
|
|
</td><td headers="hd_h_Severity.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Normal</td><td headers="hd_h_Severity.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>1.0-1.5</td><td headers="hd_h_Severity.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>1.5-2.5</td><td headers="hd_h_Severity.Tc_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>2.5-5</td><td headers="hd_h_Severity.Tc_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>5</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobSeverityTd"><div id="Severity.Td" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548241/table/Severity.Td/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Severity.Td_lrgtbl__"><table><thead><tr><th id="hd_h_Severity.Td_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FEATURE</th><th id="hd_h_Severity.Td_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Grade 0</th><th id="hd_h_Severity.Td_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Grade 1</th><th id="hd_h_Severity.Td_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Grade 2</th><th id="hd_h_Severity.Td_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Grade 3</th><th id="hd_h_Severity.Td_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Grade 4</th></tr></thead><tbody><tr><td headers="hd_h_Severity.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>ALT</b>
|
|
</td><td headers="hd_h_Severity.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Normal</td><td headers="hd_h_Severity.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>1.0-3.0</td><td headers="hd_h_Severity.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>3.0-5.0</td><td headers="hd_h_Severity.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>5.0-20</td><td headers="hd_h_Severity.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>20</td></tr><tr><td headers="hd_h_Severity.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>AST</b>
|
|
</td><td headers="hd_h_Severity.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Normal</td><td headers="hd_h_Severity.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>1.0-3.0</td><td headers="hd_h_Severity.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>3.0-5.0</td><td headers="hd_h_Severity.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>5.0-20</td><td headers="hd_h_Severity.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>20</td></tr><tr><td headers="hd_h_Severity.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Alkaline Phosphatase</b>
|
|
</td><td headers="hd_h_Severity.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Normal</td><td headers="hd_h_Severity.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>1.0-2.5</td><td headers="hd_h_Severity.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>2.5-5.0</td><td headers="hd_h_Severity.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>5.0-20</td><td headers="hd_h_Severity.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>20</td></tr><tr><td headers="hd_h_Severity.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>GGT</b>
|
|
</td><td headers="hd_h_Severity.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Normal</td><td headers="hd_h_Severity.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>1.0-2.5</td><td headers="hd_h_Severity.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>2.5-5.0</td><td headers="hd_h_Severity.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>5.0-20</td><td headers="hd_h_Severity.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>20</td></tr><tr><td headers="hd_h_Severity.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Bilirubin</b>
|
|
</td><td headers="hd_h_Severity.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Normal</td><td headers="hd_h_Severity.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>1.0-1.5</td><td headers="hd_h_Severity.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>1.5-3.0</td><td headers="hd_h_Severity.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>3.0-10</td><td headers="hd_h_Severity.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>10</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal105 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|